InnovAge vs Omada Health
INNV and OMDA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INNV and OMDA compare
InnovAge is the larger company, worth 1.4 times as much as Omada Health ($1.3B against $933M).
Omada Health grew revenue faster over the last twelve months (43.3% versus 15.9% for InnovAge).
Omada Health keeps more of each dollar of sales as profit, with a net margin of 4.2% compared with −0.26% at InnovAge.
Omada Health scores higher on the StockData Score (13 against 10 for InnovAge), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INNV | OMDA |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $933M |
| Share price | $9.50 | $15.24 |
| Change, 1 year | 88.1% | −26.2% |
| Change, 5 years | 13.0% | – |
| Beta (5Y) | 0.68 | 2.38 |
| Employees | 2,500 | 916 |
| StockData Score | ||
| Total score | 10 | 13 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 | 3 |
| Performance score | 2 | 3 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.3× (better) | 2.8× |
| P/B | 5.5× | 3.4× (better) |
| EV/EBITDA | 50.8× (better) | 52.7× |
| P/FCF | 25.7× (better) | 33.1× |
| FCF yield | 3.9% (better) | 3.0% |
| Fair value | $5.78 | $9.26 |
| Margin of safety | −64.3% (better) | −64.5% |
| Growth | ||
| Revenue growth (TTM) | 15.9% | 43.3% (better) |
| Revenue growth, 5Y average | 9.2% | – |
| Profitability | ||
| Gross margin | 23.0% | 70.7% (better) |
| Operating margin | 0.26% | 2.1% (better) |
| Net margin | −0.26% | 4.2% (better) |
| FCF margin | 5.1% | 8.5% (better) |
| Return on equity | −1.1% | 5.7% (better) |
| Return on invested capital | 1.2% | 28.2% (better) |
| Financial health | ||
| Debt / equity | 0.20 (better) | 0.00 |
| Net debt / EBITDA | −3.93 | – |
| Interest coverage | – | 22.4× |
| Current ratio | 1.05 | 4.18 (better) |
| Altman Z-score | 4.24 | 7.47 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 13.5% | 85.9% |
| Held by insiders | – | 5.4% |
| Insider net buying, 12 months | −$227M | −$14.6M (better) |
| Short interest, % of float | – | 15.8% |
Go deeper
- INNV stock overview
- INNV income statement
- INNV valuation and score
- OMDA stock overview
- OMDA income statement
- OMDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.